Qiagen relies on companion diagnostics to keep its engine running, and the company is looking to gain some ground in the field through a new joint venture with German molecular diagnostics outfit Biotype Diagnostic.
Sequenom suffered a stinging defeat in its patent battle against Roche's Ariosa Diagnostics unit, as a U.S. appeals court ruled that the company's patent for its noninvasive prenatal test was invalid. Read more >>
Liquid biopsy tests are gaining traction within the industry as a viable alternative to traditional screening methods for cancer. A recent report by financial services firm Cowen & Co. said annual sales for the tools could surpass $10 billion, and study results are also turning up positive data in favor of the tests. Read more >>
POPULAR COMMENT THREADS
It has been a busy week for joint ventures in the diagnostics industry, with Qiagen teaming up with German outfit Biotype Diagnostics to create a new business geared toward companion diagnostic tests. Now, Luxembourg diagnostics company Eurofins is hopping on the JV bandwagon, shelling out $40 million to take a deeper dive into genetics with Emory University's Genetics Laboratory (EGL). Read more >>
Electronic medical records company Allscripts took a $200 million (or 10%) stake in drug discovery company NantHealth to strengthen their alliance focused on personalized medicine in the cancer treatment arena.
European private equity firm Cinven is snatching up German medical lab operator Synlab for €1.75 billion ($1.96 billion), continuing its dealmaking streak weeks after it announced it would shell out $1.3 billion for French diagnostics outfit Labco.
Google is teaming up with The Broad Institute of MIT and Harvard to create new ways of sharing genomic data and reduce barriers associated with storing and processing genetic information.
The National Institutes of Health has awarded more than $5 million over 5 years to diagnostics company Great Basin Scientific and Brigham Young University to develop a rapid molecular diagnostic test from whole blood for carbapenem-resistant Enterobacteriaceae (CRE).
Illumina is laying out plans for expansion, signing a 20-year lease on a 155,000-square-foot facility in Cambridge, England.
From Our Sister Sites
PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
Switzerland-based Actelion is jumping into the vaccines industry by creating Vaxxilon, a startup that will focus on synthetic carbohydrate vaccines. It has licensed exclusive rights to multiple preclinical vaccines and other technologies from the Max Planck Society and will invest up to €30 million ($33 million), which will come in tranches over three to four years.